USMIRC Myeloma News letter issue-2

Written By USMIRC

Quadruplet Victory is Official! Treatment of newly diagnosed myeloma who are eligible for transplant!

Talquetamab FDA approval? A New target therapy for relapse myeloma patients!!

Tweet of the USMIRC group

USMIRC Medal awards winners 2023

EMD in penta-RRMM patient post- BCMA treatment and post Talquetamab failure

USMIRC group work: Outcomes of VDPACE in Triple Relapsed/Refractory Multiple Myeloma

BCMA directed therapy

See more: Issue 2

USMIRC
Previous

USMIRC NEWS
Next

USMIRC myeloma News Letter_ issue 1